GRCE
Grace Therapeutics, Inc.NASDAQHealthcare$3.57+7.21%ClosedMarket Cap: $50.4M
As of 2026-04-09
Valuation
P/E (TTM)
—
PEG
—
P/B
0.93
P/S
0.00
EV/EBITDA
-4.09
DCF Value
$1.30
FCF Yield
-20.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-10.6%
ROA
-10.0%
ROIC
-15.8%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q3 2026 | $0.00 | -Infinity% | $-3.4M | $-3.2M | $-0.19 | — |
| Q2 2026 | $0.00 | NaN% | $-2.5M | $-938.0K | $-0.06 | — |
| Q1 2026 | $0.00 | NaN% | $-3.1M | $-3.4M | $-0.21 | — |
| Q4 2025 | $0.00 | -Infinity% | $-3.2M | $636.0K | $0.05 | — |
| FY 2025 | $0.00 | NaN% | $-16.7M | $-9.6M | $-0.79 | — |
| Q3 2025 | $0.00 | NaN% | $-3.7M | $-4.2M | $-0.36 | — |
| Q2 2025 | $0.00 | NaN% | $-4.8M | $-3.4M | $-0.30 | — |
| Q1 2025 | $0.00 | NaN% | $-5.0M | $-2.6M | $-0.24 | — |
| Q4 2024 | $0.00 | -Infinity% | $-3.3M | $-3.2M | $-0.34 | — |
| FY 2024 | $0.00 | -Infinity% | $-11.3M | $-12.9M | $-1.73 | — |
| Q3 2024 | $0.00 | NaN% | $-3.0M | $-2.4M | $-0.32 | — |
| Q2 2024 | $0.00 | -Infinity% | $-2.1M | $-3.3M | $-0.43 | — |